Pular para o conteúdo
Merck
Todas as fotos(3)

Key Documents

SML0005

Sigma-Aldrich

Cerivastatin sodium salt hydrate

≥98% (HPLC)

Sinônimo(s):

(3R,5S,6E)-7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid sodium salt hydrate, Rivastatin hydrate

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C26H33FNNaO5 · xH2O
Número CAS:
Peso molecular:
481.53 (anhydrous basis)
Número MDL:
Código UNSPSC:
12352200
ID de substância PubChem:
NACRES:
NA.77

Nível de qualidade

Ensaio

≥98% (HPLC)

forma

powder

atividade óptica

[α]/D +18 to +26° in ethanol

condição de armazenamento

desiccated

cor

white to tan

solubilidade

H2O: ≥5 mg/mL

originador

Bayer

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

O.[Na+].COCc1c(nc(C(C)C)c(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)c1-c2ccc(F)cc2)C(C)C

InChI

1S/C26H34FNO5.Na.H2O/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4;;/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32);;1H2/q;+1;/p-1/b11-10+;;/t19-,20-;;/m1../s1

chave InChI

NJHMEKXCHXHQPP-PZLZTSNUSA-M

Descrição geral

Cerivastatin sodium salt hydrate belongs to the statin class of lipid lowering agents. It helps in decreasing MAP kinase activation, blocking AP-1 (activator protein-1) and NF-kB (nuclear factor-kB ) binding activity, inhibiting inflammatory responses and ameliorated renal damage. It also lowers cholesterol. It is metabolized by cytochrome P450 (CYP)3A4 and (CYP)2C8. Cerivastatin sodium salt hydrate is linked to rhabdomyolysis.

Aplicação

Cerivastatin sodium salt hydrate has been used as a supplement in cell culture.
Cerivastatin sodium salt hydrate may be used in cell signaling studies.

Ações bioquímicas/fisiológicas

Accumulated macrophages in atherosclerotic plaques result in plaque rupture and thrombus formation. Cerivastatin suppresses the growth of macrophages and decreases the expression of matrix metalloproteinases and tissue factor molecules, thus reduces acute coronary events.
Cerivastatin sodium is an HMG-CoA reductase inhibitor. HMG-CoA is a key enzyme in the production of cholesterol.

Características e benefícios

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

M A Crouch
American family physician, 63(2), 309-320 (2001-02-24)
Primary and secondary prevention trials have shown that use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) to lower an elevated low-density lipoprotein cholesterol level can substantially reduce coronary events and death from coronary heart disease. In 1987
GTSE1: a novel TEAD4-E2F1 target gene involved in cell protrusions formation in triple-negative breast cancer cell models
Stelitano D, etal.
Oncotarget, 8(40), 67422-67422 (2017)
A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin
Ishikawa C, et al.
Journal of Human Genetics, 49(10), 582-585 (2004)
M Aikawa et al.
Circulation, 103(2), 276-283 (2001-02-24)
Unstable atherosclerotic plaques that cause acute coronary events usually contain abundant macrophages expressing matrix metalloproteinases (MMPs) and tissue factor (TF), molecules that probably contribute to plaque rupture and subsequent thrombus formation. Lipid lowering with HMG-CoA reductase inhibitors reduces acute coronary
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin
Mazzu AL, et al.
Clinical Pharmacology and Therapeutics, 68(4), 391-400 (2000)

Artigos

Randomized controlled clinical studies have suggested 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both primary and secondary prevention of cardiovascular disease (CVD) events.

Conteúdo relacionado

Discover Bioactive Small Molecules for Lipid Signaling Research

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica